Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drug
Alnylam Pharmaceuticals Inc. (ALNY) shares fell more than 8% premarket on Thursday after advisers to the U.S. Food and Drug Administration on Wednesday weighed the risks and benefits of the company's treatment for a serious heart condition known as ATTR-CM. The FDA advisory committee voted 9 to 3 that the benefits of the treatment, Onpattro, outweigh its risks in patients with ATTR-CM, but the committee's comments suggest that the drug's label may be limited, analysts say. BMO Capital Markets analyst Kostas Biliouris wrote in a note Wednesday that Onpattro's label will likely be limited to patients who can't get or tolerate tafamidis, the ATTR-CM treatment sold by Pfizer Inc. (PFE) as Vyndaqel and Vyndamax. The FDA advisers seemed to agree with the agency's position that Onpattro's treatment effect is small, Oppenheimer analysts wrote in a note Thursday, adding, "even in the best-case scenario of an unconditional ATTR-CM indication for Onpattro, we would expect payors to generally restrict access to those who do not adequately respond to tafamidis." Both analysts maintain outperform ratings on Alnylam shares, saying investors are more focused on the prospects for a different Alnylam product, Amvuttra. Alnylam shares are down 10.9% in the year to date, while the S&P 500 has gained 16.4%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-14-23 0815ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
US Stock Market Outlook & Valuation for May 2024
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett